Albert Bourla argues that a corporation's role is to excel in a few key areas, not to diversify like an investor. He spun off consumer and generic units to sharpen Pfizer's focus on its core strength—science and innovative medicine—believing different business types require incompatible cultures.

Despite sound science, many recent drug launches are failing. The root cause is not the data but an underinvestment in market conditioning. Cautious investors and tighter budgets mean companies are starting their educational and scientific storytelling efforts too late, failing to prepare the market adequately.

The industry's costly drug development failures are often attributed to clinical issues. However, the root cause is frequently organizational: siloed teams, misaligned incentives, and hierarchical leadership that stifle the knowledge sharing necessary for success.

Companies run numerous disconnected AI pilots in R&D, commercial, and other silos, each with its own metrics. This fragmented approach prevents enterprise-wide impact and disconnects AI investment from C-suite goals like share price or revenue growth. The core problem is strategic, not technical.

Pfizer's CEO was named a "Best CEO" not for pipeline success but for effectively managing political pressure from the Trump administration. He made deals that appeased the White House on drug pricing without harming shareholder value, highlighting how a modern pharma CEO's job now heavily involves navigating the political landscape.

Top pharma CEOs are 'control freaks' who can demand predictable returns from sales and manufacturing. This personality trait creates a fundamental conflict with R&D, where outcomes are inherently uncertain, driving a futile and frustrating push to systematize innovation.

Successful biotech leadership requires a clear decision-making hierarchy. Dr. Bahija Jallal advocates for a framework where patient welfare is paramount, followed by scientific rigor. Financial success is treated as a byproduct of excelling in the first two areas, not the primary goal.

Once profitable, biotechs should transition from a high-risk R&D culture to a more business-oriented model. Biogen's persistent, high-risk pursuit of Alzheimer's drugs demonstrates a common failure to make this strategic shift, wasting capital and acting more like a startup than a mature business.

R&D departments in large pharmaceutical companies often resist repurposing projects. Their leaders are rewarded for discovering new chemical entities, not for finding new applications for existing drugs, creating an internal funding barrier that business units must overcome.